Skip to main content

The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients.

Publication ,  Journal Article
Heimberger, AB; Sampson, JH
Published in: Expert Opin Biol Ther
August 2009

Conventional therapies for glioblastoma multiforme (GBM) fail to target tumor cells exclusively, resulting in non-specific toxicity. Immune targeting of tumor-specific mutations may allow for more precise eradication of neoplastic cells. EGFR variant III (EGFRvIII) is a tumor-specific mutation that is widely expressed in GBM and other neoplasms and its expression enhances tumorigenicity. This in-frame deletion mutation splits a codon, resulting in a novel glycine at the fusion junction producing a tumor-specific epitope target for cellular or humoral immunotherapy. We have previously shown that vaccination with a peptide that spans the EGFRvIII fusion junction (PEPvIII-KLH/CDX-110) is an efficacious immunotherapy in syngeneic murine models. In this review, we summarize our results in GBM patients targeting this mutation in multiple, multi-institutional Phase II immunotherapy trials. These trials demonstrated that a selected population of GBM patients who received vaccines targeting EGFRvIII had an unexpectedly long survival time. Further therapeutic strategies and potential pitfalls of using this approach are discussed.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Expert Opin Biol Ther

DOI

EISSN

1744-7682

Publication Date

August 2009

Volume

9

Issue

8

Start / End Page

1087 / 1098

Location

England

Related Subject Headings

  • Prognosis
  • Peptides
  • Mutation
  • Mice
  • Immunotherapy
  • Immunology
  • Humans
  • Hemocyanins
  • Glioblastoma
  • ErbB Receptors
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Heimberger, A. B., & Sampson, J. H. (2009). The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. Expert Opin Biol Ther, 9(8), 1087–1098. https://doi.org/10.1517/14712590903124346
Heimberger, Amy B., and John H. Sampson. “The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients.Expert Opin Biol Ther 9, no. 8 (August 2009): 1087–98. https://doi.org/10.1517/14712590903124346.
Heimberger AB, Sampson JH. The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. Expert Opin Biol Ther. 2009 Aug;9(8):1087–98.
Heimberger, Amy B., and John H. Sampson. “The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients.Expert Opin Biol Ther, vol. 9, no. 8, Aug. 2009, pp. 1087–98. Pubmed, doi:10.1517/14712590903124346.
Heimberger AB, Sampson JH. The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. Expert Opin Biol Ther. 2009 Aug;9(8):1087–1098.

Published In

Expert Opin Biol Ther

DOI

EISSN

1744-7682

Publication Date

August 2009

Volume

9

Issue

8

Start / End Page

1087 / 1098

Location

England

Related Subject Headings

  • Prognosis
  • Peptides
  • Mutation
  • Mice
  • Immunotherapy
  • Immunology
  • Humans
  • Hemocyanins
  • Glioblastoma
  • ErbB Receptors